epidermal-growth-factor and amlexanox

epidermal-growth-factor has been researched along with amlexanox* in 2 studies

Other Studies

2 other study(ies) available for epidermal-growth-factor and amlexanox

ArticleYear
Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.
    PloS one, 2016, Volume: 11, Issue:8

    The human S100A4 protein binds calcium, resulting in a change in its conformation to promote the interaction with its target protein. Human epidermal growth factor (EGF) is the target protein of S100A4 and a critical ligand of the receptor EGFR. The EGF/EGFR system promotes cell survival, differentiation, and growth by activating several signaling pathways. Amlexanox is an anti-inflammatory and anti-allergic drug that is used to treat recurrent aphthous ulcers. In the present study, we determined that amlexanox interacts with S100A4 using heteronuclear single quantum correlation titration. We elucidated the interactions of S100A4 with EGF and amlexanox using fluorescence and nuclear magnetic resonance spectroscopy. We generated two binary models (for the S100A4-EGF and S100A4-amlexanox complexes) and observed that amlexanox and EGF share a similar binding region in mS100A4. We also used a WST-1 assay to investigate the bioactivity of S100A4, EGF, and amlexanox, and found that amlexanox blocks the binding between S100A4 and EGF, and is therefore useful for the development of new anti-proliferation drugs.

    Topics: Aminopyridines; Anti-Allergic Agents; Anti-Inflammatory Agents; Calcium; Cell Differentiation; Cell Proliferation; Cell Survival; Epidermal Growth Factor; Fluorescence; Humans; Ligands; Magnetic Resonance Spectroscopy; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; S100 Calcium-Binding Protein A4; Signal Transduction; Trypsin

2016
Inhibition by amoxanox (AA-673) of the immunologically, leukotriene D4- or platelet-activating factor-stimulated bronchoconstriction in guinea pigs and rats.
    International archives of allergy and applied immunology, 1985, Volume: 77, Issue:3

    We studied the effects of amoxanox (AA-673) on allergic asthma and spasmogen-induced bronchoconstriction in guinea pigs and rats. Amoxanox given orally or parenterally inhibited allergic asthma mediated by IgE, IgG1, or heterologous IgG in guinea pigs and by IgE in rats. This compound also reduced leukotriene D4- and platelet-activating factor-induced bronchoconstriction in guinea pigs, strongly suggesting an antagonistic activity against slow reacting substance of anaphylaxis (SRS-A). Histamine- or acetylcholine-induced bronchoconstriction was not significantly affected by amoxanox. These antiasthmatic effects of amoxanox seem to be associated with an inhibition of the release of chemical mediators such as histamine and SRS-A and with an antagonism against SRS-A.

    Topics: Aminopyridines; Animals; Asthma; Bronchi; Cromolyn Sodium; Epidermal Growth Factor; Female; Guinea Pigs; Histamine Release; Immunoglobulin E; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; SRS-A

1985